ADBE,Adobe fixes Flash Player bug used in attack on Syrian gov't website April 28 Adobe Systems Inc released an update on Monday to its widely used Flash Player software to fix a bug that cybersecurity company Kaspersky Lab said had been exploited to attack visitors to a Syrian government website. 
AGN,Pharma event risk hits investorsExclusive: Allergan eyes new takeover bid for Shire - sources LONDON/NEW YORK Allergan Inc , facing an unsolicited bid from Valeant Pharmaceuticals International Inc , is preparing to approach Shire Plc  again about a potential takeover after being rebuffed in recent months, people familiar with the matter said on Monday.  Exclusive: Allergan eyes new takeover bid for Shire - sources LONDON/NEW YORK Allergan Inc , facing an unsolicited bid from Valeant Pharmaceuticals International Inc , is preparing to approach Shire Plc  again about a potential takeover after being rebuffed in recent months, people familiar with the matter said on Monday. (This story originally appeared on IFR, a Thomson Reuters publication)Exclusive: Allergan eyes new takeover bid for Shire - sources LONDON/NEW YORK Allergan Inc , facing an unsolicited bid from Valeant Pharmaceuticals International Inc , is preparing to approach Shire Plc  again about a potential takeover after being rebuffed in recent months, people familiar with the matter said on Monday.  
GOOGL,Google says self-driving car tests now focused on city driving SAN FRANCISCO, April 28 Google Inc  said it has begun testing its self-driving cars on city streets, a crucial new phase in its quest to eventually make the technology a standard feature in automobiles. 
GOOG,Google says self-driving car tests now focused on city driving SAN FRANCISCO, April 28 Google Inc  said it has begun testing its self-driving cars on city streets, a crucial new phase in its quest to eventually make the technology a standard feature in automobiles. 
AMZN,India Morning Call-Global MarketsGerman watchdog critical of Asics sales practiceCORRECTED-US STOCKS-Nasdaq falls, led by Facebook and Amazon; Dow upUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca  US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca (Corrects first paragraph to show Bank of America weighed on S&P; 500, not Dow)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca   CORRECTED-US STOCKS-Nasdaq falls, led by Facebook and Amazon; Dow upUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca  US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca (Corrects first paragraph to show Bank of America weighed on S&P; 500, not Dow)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca  DUESSELDORF, Germany, April 28 The German cartel office expressed concern on Monday over the way sports goods maker Asics Corp limits sales of its products online to authorised dealers.CORRECTED-US STOCKS-Nasdaq falls, led by Facebook and Amazon; Dow upUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca  US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca (Corrects first paragraph to show Bank of America weighed on S&P; 500, not Dow)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca    German watchdog critical of Asics sales practiceCORRECTED-US STOCKS-Nasdaq falls, led by Facebook and Amazon; Dow upUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca  US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca (Corrects first paragraph to show Bank of America weighed on S&P; 500, not Dow)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca   CORRECTED-US STOCKS-Nasdaq falls, led by Facebook and Amazon; Dow upUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca  US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca (Corrects first paragraph to show Bank of America weighed on S&P; 500, not Dow)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca  DUESSELDORF, Germany, April 28 The German cartel office expressed concern on Monday over the way sports goods maker Asics Corp limits sales of its products online to authorised dealers.CORRECTED-US STOCKS-Nasdaq falls, led by Facebook and Amazon; Dow upUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca  US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca (Corrects first paragraph to show Bank of America weighed on S&P; 500, not Dow)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca   NEW YORK - U.S. stocks dropped on Friday, pulled lower by a selloff in consumer discretionary stocks as bellwether names Amazon.com and Ford Motor fell in the wake of their quarterly earnings.German watchdog critical of Asics sales practiceCORRECTED-US STOCKS-Nasdaq falls, led by Facebook and Amazon; Dow upUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca  US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca (Corrects first paragraph to show Bank of America weighed on S&P; 500, not Dow)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca   CORRECTED-US STOCKS-Nasdaq falls, led by Facebook and Amazon; Dow upUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca  US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca (Corrects first paragraph to show Bank of America weighed on S&P; 500, not Dow)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca  DUESSELDORF, Germany, April 28 The German cartel office expressed concern on Monday over the way sports goods maker Asics Corp limits sales of its products online to authorised dealers.CORRECTED-US STOCKS-Nasdaq falls, led by Facebook and Amazon; Dow upUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca  US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca (Corrects first paragraph to show Bank of America weighed on S&P; 500, not Dow)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dips * Pfizer works on next move in takeover bid for Astrazeneca    
AMP,Ameriprise Financial profit rises; sets $2.5 bln stock buyback April 28 Financial services company Ameriprise Financial Inc reported a 19 percent rise in first-quarter profit, driven by strong income from its wealth management business and said it would buy back an additional $2.5 billion in stock. 
AAPL,Apple coming back for moreUS STOCKS SNAPSHOT-S&P; 500 ends up with Apple after volatile sessionUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple  GLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple * Pfizer works on next move in takeover bid for AstrazenecaGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple   US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple  GLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple * Pfizer works on next move in takeover bid for AstrazenecaGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple  NEW YORK, April 28 The S&P; 500 ended higher on Monday after a volatile session, as gains in Apple and Pfizer helped offset another round of selling in some high-growth tech shares.US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple  GLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple * Pfizer works on next move in takeover bid for AstrazenecaGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple    US STOCKS SNAPSHOT-S&P; 500 ends up with Apple after volatile sessionUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple  GLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple * Pfizer works on next move in takeover bid for AstrazenecaGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple   US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple  GLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple * Pfizer works on next move in takeover bid for AstrazenecaGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple  NEW YORK, April 28 The S&P; 500 ended higher on Monday after a volatile session, as gains in Apple and Pfizer helped offset another round of selling in some high-growth tech shares.US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple  GLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple * Pfizer works on next move in takeover bid for AstrazenecaGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple   (This story originally appeared on IFR, a Thomson Reuters publication)US STOCKS SNAPSHOT-S&P; 500 ends up with Apple after volatile sessionUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple  GLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple * Pfizer works on next move in takeover bid for AstrazenecaGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple   US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple  GLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple * Pfizer works on next move in takeover bid for AstrazenecaGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple  NEW YORK, April 28 The S&P; 500 ended higher on Monday after a volatile session, as gains in Apple and Pfizer helped offset another round of selling in some high-growth tech shares.US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple  GLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple * Pfizer works on next move in takeover bid for AstrazenecaGLOBAL MARKETS-Stocks gain on merger speculation, crude oil falls * Wall St rebounds on merger speculation, rotation into Apple    
T,AT&T;, Honeywell to launch 4G in-flight broadband systemRPT-AT&T;, Honeywell to launch 4G in-flight broadband systemUPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc.  UPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc. SEATTLE, April 28 AT&T; Inc and Honeywell International Inc said on Monday that they have agreed to launch a high-speed 4G LTE-based in-flight connectivity service for airlines and passengers in commercial, business and general aviation in the U.S.UPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc.   RPT-AT&T;, Honeywell to launch 4G in-flight broadband systemUPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc.  UPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc. SEATTLE, April 28 AT&T; Inc and Honeywell International Inc said on Monday that they have agreed to launch a high-speed 4G LTE-based in-flight connectivity service for airlines and passengers in commercial, business and general aviation in the U.S.UPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc.  SEATTLE, April 28 AT&T; Inc and Honeywell International Inc said on Monday that they have agreed to launch a high-speed 4G LTE-based in-flight connectivity service for airlines and passengers in commercial, business and general aviation in the U.S.RPT-AT&T;, Honeywell to launch 4G in-flight broadband systemUPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc.  UPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc. SEATTLE, April 28 AT&T; Inc and Honeywell International Inc said on Monday that they have agreed to launch a high-speed 4G LTE-based in-flight connectivity service for airlines and passengers in commercial, business and general aviation in the U.S.UPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc.   
BAC,Bank of America's head of Asia equity syndicate resignsBofA suspends stock buyback, dividend increaseBrazil's Oi offer seen pricing at bottom, demand strong, sources say SAO PAULO, April 28 Grupo Oi SA, Brazil's biggest fixed-line telephone carrier, on Monday got closer to its planned merger with Portugal Telecom SGPS SA as investors were willing to place more than enough bids in a share offering expected to be worth at least 8 billion reais ($3.6 billion), sources told Reuters.  Brazil's Oi offer seen pricing at bottom, demand strong, sources say SAO PAULO, April 28 Grupo Oi SA, Brazil's biggest fixed-line telephone carrier, on Monday got closer to its planned merger with Portugal Telecom SGPS SA as investors were willing to place more than enough bids in a share offering expected to be worth at least 8 billion reais ($3.6 billion), sources told Reuters. April 28 Bank of America Corp said it would suspend its $4 billion stock buyback program and the planned increase in its quarterly dividend after it miscalculated the treatment of certain structured notes related to its acquisition of Merrill Lynch in 2009.Brazil's Oi offer seen pricing at bottom, demand strong, sources say SAO PAULO, April 28 Grupo Oi SA, Brazil's biggest fixed-line telephone carrier, on Monday got closer to its planned merger with Portugal Telecom SGPS SA as investors were willing to place more than enough bids in a share offering expected to be worth at least 8 billion reais ($3.6 billion), sources told Reuters.   BofA suspends stock buyback, dividend increaseBrazil's Oi offer seen pricing at bottom, demand strong, sources say SAO PAULO, April 28 Grupo Oi SA, Brazil's biggest fixed-line telephone carrier, on Monday got closer to its planned merger with Portugal Telecom SGPS SA as investors were willing to place more than enough bids in a share offering expected to be worth at least 8 billion reais ($3.6 billion), sources told Reuters.  Brazil's Oi offer seen pricing at bottom, demand strong, sources say SAO PAULO, April 28 Grupo Oi SA, Brazil's biggest fixed-line telephone carrier, on Monday got closer to its planned merger with Portugal Telecom SGPS SA as investors were willing to place more than enough bids in a share offering expected to be worth at least 8 billion reais ($3.6 billion), sources told Reuters. April 28 Bank of America Corp said it would suspend its $4 billion stock buyback program and the planned increase in its quarterly dividend after it miscalculated the treatment of certain structured notes related to its acquisition of Merrill Lynch in 2009.Brazil's Oi offer seen pricing at bottom, demand strong, sources say SAO PAULO, April 28 Grupo Oi SA, Brazil's biggest fixed-line telephone carrier, on Monday got closer to its planned merger with Portugal Telecom SGPS SA as investors were willing to place more than enough bids in a share offering expected to be worth at least 8 billion reais ($3.6 billion), sources told Reuters.  HONG KONG, April 28 Bank of America Corp's  Asia head of equity syndicate, Nicholas Lee, has resigned after a tenure of nearly 14 years with the bank, a Hong Kong-based spokesman confirmed on Monday.BofA suspends stock buyback, dividend increaseBrazil's Oi offer seen pricing at bottom, demand strong, sources say SAO PAULO, April 28 Grupo Oi SA, Brazil's biggest fixed-line telephone carrier, on Monday got closer to its planned merger with Portugal Telecom SGPS SA as investors were willing to place more than enough bids in a share offering expected to be worth at least 8 billion reais ($3.6 billion), sources told Reuters.  Brazil's Oi offer seen pricing at bottom, demand strong, sources say SAO PAULO, April 28 Grupo Oi SA, Brazil's biggest fixed-line telephone carrier, on Monday got closer to its planned merger with Portugal Telecom SGPS SA as investors were willing to place more than enough bids in a share offering expected to be worth at least 8 billion reais ($3.6 billion), sources told Reuters. April 28 Bank of America Corp said it would suspend its $4 billion stock buyback program and the planned increase in its quarterly dividend after it miscalculated the treatment of certain structured notes related to its acquisition of Merrill Lynch in 2009.Brazil's Oi offer seen pricing at bottom, demand strong, sources say SAO PAULO, April 28 Grupo Oi SA, Brazil's biggest fixed-line telephone carrier, on Monday got closer to its planned merger with Portugal Telecom SGPS SA as investors were willing to place more than enough bids in a share offering expected to be worth at least 8 billion reais ($3.6 billion), sources told Reuters.   
BA,Boeing to ask Japanese firms to build a fifth of 777X -sourcesNorwegian Air suspends talks to buy 20 new Boeing DreamlinersNorwegian Air suspends talks to buy 20 new Boeing DreamlinersUPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway    UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   OSLO Low-cost carrier Norwegian Air  has put on hold talks to buy 20 new Dreamliners from Boeing  because of a delay in receiving U.S. Department of Transportation approval for its long haul plans, Chief Executive Bjoern Kjos said in a letter.UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway     Norwegian Air suspends talks to buy 20 new Boeing DreamlinersUPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway    UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   OSLO Low-cost carrier Norwegian Air  has put on hold talks to buy 20 new Dreamliners from Boeing  because of a delay in receiving U.S. Department of Transportation approval for its long haul plans, Chief Executive Bjoern Kjos said in a letter.UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway    OSLO, April 28 Low-cost carrier Norwegian Air  has put on hold talks to buy 20 new Dreamliners from Boeing because of a delay in receiving U.S. Department of Transportation approval for its long haul plans, Chief Executive Bjoern Kjos said in a letter.Norwegian Air suspends talks to buy 20 new Boeing DreamlinersUPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway    UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   OSLO Low-cost carrier Norwegian Air  has put on hold talks to buy 20 new Dreamliners from Boeing  because of a delay in receiving U.S. Department of Transportation approval for its long haul plans, Chief Executive Bjoern Kjos said in a letter.UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway      Norwegian Air suspends talks to buy 20 new Boeing DreamlinersNorwegian Air suspends talks to buy 20 new Boeing DreamlinersUPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway    UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   OSLO Low-cost carrier Norwegian Air  has put on hold talks to buy 20 new Dreamliners from Boeing  because of a delay in receiving U.S. Department of Transportation approval for its long haul plans, Chief Executive Bjoern Kjos said in a letter.UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway     Norwegian Air suspends talks to buy 20 new Boeing DreamlinersUPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway    UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   OSLO Low-cost carrier Norwegian Air  has put on hold talks to buy 20 new Dreamliners from Boeing  because of a delay in receiving U.S. Department of Transportation approval for its long haul plans, Chief Executive Bjoern Kjos said in a letter.UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway    OSLO, April 28 Low-cost carrier Norwegian Air  has put on hold talks to buy 20 new Dreamliners from Boeing because of a delay in receiving U.S. Department of Transportation approval for its long haul plans, Chief Executive Bjoern Kjos said in a letter.Norwegian Air suspends talks to buy 20 new Boeing DreamlinersUPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway    UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   OSLO Low-cost carrier Norwegian Air  has put on hold talks to buy 20 new Dreamliners from Boeing  because of a delay in receiving U.S. Department of Transportation approval for its long haul plans, Chief Executive Bjoern Kjos said in a letter.UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway     TOKYO, April 28 Boeing Co has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries, to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asia partner in commercial jetliners, two sources with knowledge of the U.S. company's production plan said.Norwegian Air suspends talks to buy 20 new Boeing DreamlinersNorwegian Air suspends talks to buy 20 new Boeing DreamlinersUPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway    UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   OSLO Low-cost carrier Norwegian Air  has put on hold talks to buy 20 new Dreamliners from Boeing  because of a delay in receiving U.S. Department of Transportation approval for its long haul plans, Chief Executive Bjoern Kjos said in a letter.UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway     Norwegian Air suspends talks to buy 20 new Boeing DreamlinersUPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway    UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   OSLO Low-cost carrier Norwegian Air  has put on hold talks to buy 20 new Dreamliners from Boeing  because of a delay in receiving U.S. Department of Transportation approval for its long haul plans, Chief Executive Bjoern Kjos said in a letter.UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway    OSLO, April 28 Low-cost carrier Norwegian Air  has put on hold talks to buy 20 new Dreamliners from Boeing because of a delay in receiving U.S. Department of Transportation approval for its long haul plans, Chief Executive Bjoern Kjos said in a letter.Norwegian Air suspends talks to buy 20 new Boeing DreamlinersUPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway    UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   OSLO Low-cost carrier Norwegian Air  has put on hold talks to buy 20 new Dreamliners from Boeing  because of a delay in receiving U.S. Department of Transportation approval for its long haul plans, Chief Executive Bjoern Kjos said in a letter.UPDATE 2-Japan to keep its share of production of Boeing's new 777X aircraftJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway   Japan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  * Boeing plans higher output rate for 777X than 777 -sourceJapan to keep its share of production of Boeing's new 777X aircraftUPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway  UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway TOKYO Boeing Co  has lined up Japanese companies, including Mitsubishi Heavy Industries  and Kawasaki Heavy Industries , to build one-fifth of its latest plane, the 777X, retaining Japan as its key Asian partner in commercial jetliners, two sources with knowledge of the plans said.UPDATE 1-Norwegian Air halts talks to buy Dreamliners, may quit Ireland * CEO says in letter that may rebase long-haul fleet in Norway      
CVX,U.S. court revives oil companies' lawsuit over WWII site cleanup April 28 A divided U.S. appeals court on Monday revived efforts by oil companies to force the federal government to cover their costs to clean up a southern California site where they had dumped toxic sludge during World War Two. 
CMCSA,Comcast to lose 3.9 mln subscribers as part of cable dealAOL, Microsoft lure advertisers with TV-style showsUPDATE 4-Comcast in deal with Charter as it seeks approval for TWCComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."    Comcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   * Comcast seeking regulatory approval for Time Warner Cable dealComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."     UPDATE 4-Comcast in deal with Charter as it seeks approval for TWCComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."    Comcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   * Comcast seeking regulatory approval for Time Warner Cable dealComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."    NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.UPDATE 4-Comcast in deal with Charter as it seeks approval for TWCComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."    Comcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   * Comcast seeking regulatory approval for Time Warner Cable dealComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."      AOL, Microsoft lure advertisers with TV-style showsUPDATE 4-Comcast in deal with Charter as it seeks approval for TWCComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."    Comcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   * Comcast seeking regulatory approval for Time Warner Cable dealComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."     UPDATE 4-Comcast in deal with Charter as it seeks approval for TWCComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."    Comcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   * Comcast seeking regulatory approval for Time Warner Cable dealComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."    NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.UPDATE 4-Comcast in deal with Charter as it seeks approval for TWCComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."    Comcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   * Comcast seeking regulatory approval for Time Warner Cable dealComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."     April 28 Comcast Corp said it would sell businesses resulting in a loss of 3.9 million video customers as part of its proposed $45.2 billion merger with Time Warner Cable Inc.AOL, Microsoft lure advertisers with TV-style showsUPDATE 4-Comcast in deal with Charter as it seeks approval for TWCComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."    Comcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   * Comcast seeking regulatory approval for Time Warner Cable dealComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."     UPDATE 4-Comcast in deal with Charter as it seeks approval for TWCComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."    Comcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   * Comcast seeking regulatory approval for Time Warner Cable dealComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."    NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.UPDATE 4-Comcast in deal with Charter as it seeks approval for TWCComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."    Comcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   * Comcast seeking regulatory approval for Time Warner Cable dealComcast in deal with Charter as it seeks approval for TWCDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. |Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  VideoDeals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."   Deals of the day- Mergers and acquisitionsUnivision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."  Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences." (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)Univision says Comcast buy of TWC could be 'bad for Hispanic audiences' WASHINGTON, April 28 The head of the Spanish-language television network Univision said on Monday that Comcast Corp's plan to buy rival Time Warner Cable Inc could be "bad for Hispanic audiences."      
GLW,DIARY-U.S. MEETINGS/WEEK AHEADCorning reports 26 pct rise in revenueUPDATE 1-Corning expects smaller price declines April 28 Specialty glass maker Corning Inc , best known for its Gorilla glass used in smartphones and tablets, said it expected LCD glass price declines to be "significantly less" in the current quarter compared with the first quarter.  UPDATE 1-Corning expects smaller price declines April 28 Specialty glass maker Corning Inc , best known for its Gorilla glass used in smartphones and tablets, said it expected LCD glass price declines to be "significantly less" in the current quarter compared with the first quarter. April 28 Specialty glass maker Corning Inc , best known for its Gorilla glass used in smartphones, reported a 26 percent rise in quarterly revenue, slightly missing analysts' average estimate.UPDATE 1-Corning expects smaller price declines April 28 Specialty glass maker Corning Inc , best known for its Gorilla glass used in smartphones and tablets, said it expected LCD glass price declines to be "significantly less" in the current quarter compared with the first quarter.   Corning reports 26 pct rise in revenueUPDATE 1-Corning expects smaller price declines April 28 Specialty glass maker Corning Inc , best known for its Gorilla glass used in smartphones and tablets, said it expected LCD glass price declines to be "significantly less" in the current quarter compared with the first quarter.  UPDATE 1-Corning expects smaller price declines April 28 Specialty glass maker Corning Inc , best known for its Gorilla glass used in smartphones and tablets, said it expected LCD glass price declines to be "significantly less" in the current quarter compared with the first quarter. April 28 Specialty glass maker Corning Inc , best known for its Gorilla glass used in smartphones, reported a 26 percent rise in quarterly revenue, slightly missing analysts' average estimate.UPDATE 1-Corning expects smaller price declines April 28 Specialty glass maker Corning Inc , best known for its Gorilla glass used in smartphones and tablets, said it expected LCD glass price declines to be "significantly less" in the current quarter compared with the first quarter.  THOMSON REUTERS, Apr 28,2014 - Corporate Meetings for US companies for Week ahead.         S&P; 500 Earnings - Weekly           S&P; 500 Earnings - Day Ahead        Non S&P; 500 - Weekly               Non S&P; 500 - Day Ahead             ConferenceCall/Webcast - Weekly    ConferenceCall/Webcast - Day        S&P; 500 Earnings - Monthly           Meetings - Day Ahead                Economic Indicators                  Dividends                           Daily earnings hits & misses         Federal ReseCorning reports 26 pct rise in revenueUPDATE 1-Corning expects smaller price declines April 28 Specialty glass maker Corning Inc , best known for its Gorilla glass used in smartphones and tablets, said it expected LCD glass price declines to be "significantly less" in the current quarter compared with the first quarter.  UPDATE 1-Corning expects smaller price declines April 28 Specialty glass maker Corning Inc , best known for its Gorilla glass used in smartphones and tablets, said it expected LCD glass price declines to be "significantly less" in the current quarter compared with the first quarter. April 28 Specialty glass maker Corning Inc , best known for its Gorilla glass used in smartphones, reported a 26 percent rise in quarterly revenue, slightly missing analysts' average estimate.UPDATE 1-Corning expects smaller price declines April 28 Specialty glass maker Corning Inc , best known for its Gorilla glass used in smartphones and tablets, said it expected LCD glass price declines to be "significantly less" in the current quarter compared with the first quarter.   
XOM,Exxon's Papua New Guinea project starts LNG production before schedule April 28 Exxon Mobil Corp said its project in Papua New Guinea had started production of liquefied natural gas (LNG) ahead of schedule. 
FB,CORRECTED-US STOCKS-Nasdaq falls, led by Facebook and Amazon; Dow up (Corrects first paragraph to show Bank of America weighed on S&P; 500, not Dow) 
BEN,Franklin Resources posts outflows amid emerging market concerns BOSTON, April 28 Asset manager Franklin Resources Inc said on Monday investors pulled $7.1 billion from its funds in the three months ended March 31 and that they have raised questions about its holdings in volatile regions such as Ukraine. 
GD,General Dynamics, Huntington win $17.6 bln U.S. Navy submarine dealUPDATE 1-General Dynamics, Huntington win huge U.S. Navy contractGeneral Dynamics, Huntington win huge U.S. Navy contract WASHINGTON The U.S. Navy on Monday awarded a $17.6 billion contract for 10 more Virginia-class, nuclear-powered attack submarines to General Dynamics Corp  and its major subcontractor, Huntington Ingalls Industries Inc , the largest ever Navy shipbuilding contract.  General Dynamics, Huntington win huge U.S. Navy contract WASHINGTON The U.S. Navy on Monday awarded a $17.6 billion contract for 10 more Virginia-class, nuclear-powered attack submarines to General Dynamics Corp  and its major subcontractor, Huntington Ingalls Industries Inc , the largest ever Navy shipbuilding contract. WASHINGTON, April 28 The U.S. Navy on Monday awarded a $17.6 billion contract for 10 more Virginia-class, nuclear-powered attack submarines to General Dynamics Corp  and its major subcontractor, Huntington Ingalls Industries Inc, the largest ever Navy shipbuilding contract.General Dynamics, Huntington win huge U.S. Navy contract WASHINGTON The U.S. Navy on Monday awarded a $17.6 billion contract for 10 more Virginia-class, nuclear-powered attack submarines to General Dynamics Corp  and its major subcontractor, Huntington Ingalls Industries Inc , the largest ever Navy shipbuilding contract.   UPDATE 1-General Dynamics, Huntington win huge U.S. Navy contractGeneral Dynamics, Huntington win huge U.S. Navy contract WASHINGTON The U.S. Navy on Monday awarded a $17.6 billion contract for 10 more Virginia-class, nuclear-powered attack submarines to General Dynamics Corp  and its major subcontractor, Huntington Ingalls Industries Inc , the largest ever Navy shipbuilding contract.  General Dynamics, Huntington win huge U.S. Navy contract WASHINGTON The U.S. Navy on Monday awarded a $17.6 billion contract for 10 more Virginia-class, nuclear-powered attack submarines to General Dynamics Corp  and its major subcontractor, Huntington Ingalls Industries Inc , the largest ever Navy shipbuilding contract. WASHINGTON, April 28 The U.S. Navy on Monday awarded a $17.6 billion contract for 10 more Virginia-class, nuclear-powered attack submarines to General Dynamics Corp  and its major subcontractor, Huntington Ingalls Industries Inc, the largest ever Navy shipbuilding contract.General Dynamics, Huntington win huge U.S. Navy contract WASHINGTON The U.S. Navy on Monday awarded a $17.6 billion contract for 10 more Virginia-class, nuclear-powered attack submarines to General Dynamics Corp  and its major subcontractor, Huntington Ingalls Industries Inc , the largest ever Navy shipbuilding contract.  WASHINGTON, April 28 The U.S. Navy on Monday awarded a $17.6 billion contract for 10 more Virginia-class attack submarines to General Dynamics Corp and its major subcontractor, Huntington Ingalls Industries Inc, the largest Navy shipbuilding contract ever.UPDATE 1-General Dynamics, Huntington win huge U.S. Navy contractGeneral Dynamics, Huntington win huge U.S. Navy contract WASHINGTON The U.S. Navy on Monday awarded a $17.6 billion contract for 10 more Virginia-class, nuclear-powered attack submarines to General Dynamics Corp  and its major subcontractor, Huntington Ingalls Industries Inc , the largest ever Navy shipbuilding contract.  General Dynamics, Huntington win huge U.S. Navy contract WASHINGTON The U.S. Navy on Monday awarded a $17.6 billion contract for 10 more Virginia-class, nuclear-powered attack submarines to General Dynamics Corp  and its major subcontractor, Huntington Ingalls Industries Inc , the largest ever Navy shipbuilding contract. WASHINGTON, April 28 The U.S. Navy on Monday awarded a $17.6 billion contract for 10 more Virginia-class, nuclear-powered attack submarines to General Dynamics Corp  and its major subcontractor, Huntington Ingalls Industries Inc, the largest ever Navy shipbuilding contract.General Dynamics, Huntington win huge U.S. Navy contract WASHINGTON The U.S. Navy on Monday awarded a $17.6 billion contract for 10 more Virginia-class, nuclear-powered attack submarines to General Dynamics Corp  and its major subcontractor, Huntington Ingalls Industries Inc , the largest ever Navy shipbuilding contract.   
GE,Germany prefers Siemens tie-up with Alstom to GE deal - sourceUPDATE 6-France meets Alstom bidders with pledge to protect jobs * President Hollande meets GE, Siemens bosses about proposed deal  UPDATE 6-France meets Alstom bidders with pledge to protect jobs * President Hollande meets GE, Siemens bosses about proposed deal BERLIN, April 28 The German government would rather see Siemens take over the power arm of its French rival Alstom than have it acquired by General Electric, a government source in Berlin told Reuters on Monday.UPDATE 6-France meets Alstom bidders with pledge to protect jobs * President Hollande meets GE, Siemens bosses about proposed deal  
GM,U.S. senators ask federal agency to act on recalled GM cars WASHINGTON, April 28 Two Democratic U.S. senators on Monday called on the Department of Transportation to urge owners of 2.6 million recalled General Motors cars to stop driving them until they are repaired, which could take months as dealerships wait for replacement ignition switches. 
GS,UPDATE 4-BofA suspends buyback, div increase after capital error (Recasts throughout, adds analyst comments, background, updates stock price) 
HIG,Japan's Orix agrees to buy Hartford Japan unit for $895 millionUPDATE 1-Japan's Orix agrees to buy Hartford Japan unit for $895M * Orix to book one-time gain of Y30 bln as negative goodwill for 2014/15  UPDATE 1-Japan's Orix agrees to buy Hartford Japan unit for $895M * Orix to book one-time gain of Y30 bln as negative goodwill for 2014/15 TOKYO, April 28 Japan's financial company Orix Corp said on Monday it has agreed to buy Hartford Financial Services Group's Japanese life insurance unit for $895 million in a bid to expand its life insurance business in the world's third-largest economy.UPDATE 1-Japan's Orix agrees to buy Hartford Japan unit for $895M * Orix to book one-time gain of Y30 bln as negative goodwill for 2014/15  
HON,AT&T;, Honeywell to launch 4G in-flight broadband systemRPT-AT&T;, Honeywell to launch 4G in-flight broadband systemUPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc.  UPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc. SEATTLE, April 28 AT&T; Inc and Honeywell International Inc said on Monday that they have agreed to launch a high-speed 4G LTE-based in-flight connectivity service for airlines and passengers in commercial, business and general aviation in the U.S.UPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc.   RPT-AT&T;, Honeywell to launch 4G in-flight broadband systemUPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc.  UPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc. SEATTLE, April 28 AT&T; Inc and Honeywell International Inc said on Monday that they have agreed to launch a high-speed 4G LTE-based in-flight connectivity service for airlines and passengers in commercial, business and general aviation in the U.S.UPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc.  SEATTLE, April 28 AT&T; Inc and Honeywell International Inc said on Monday that they have agreed to launch a high-speed 4G LTE-based in-flight connectivity service for airlines and passengers in commercial, business and general aviation in the U.S.RPT-AT&T;, Honeywell to launch 4G in-flight broadband systemUPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc.  UPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc. SEATTLE, April 28 AT&T; Inc and Honeywell International Inc said on Monday that they have agreed to launch a high-speed 4G LTE-based in-flight connectivity service for airlines and passengers in commercial, business and general aviation in the U.S.UPDATE 2-AT&T;, Honeywell to challenge Gogo's airborne Web business SEATTLE, April 28 AT&T; Inc and Honeywell International Inc are teaming up to offer high-speed, in-flight Internet in the United States, the companies said on Monday, challenging industry leader Gogo Inc.   
JPM,JPMorgan reduces repo credit extension that concerns regulatorsJPMorgan reduces repo credit extension that concerns regulators JPMorgan , one of two large clearing banks in the tri-party repurchase agreement market, said on Monday that it had met targets to reduce risks of short-term loans of concern to the Federal Reserve Bank of New York and other regulators.  JPMorgan reduces repo credit extension that concerns regulators JPMorgan , one of two large clearing banks in the tri-party repurchase agreement market, said on Monday that it had met targets to reduce risks of short-term loans of concern to the Federal Reserve Bank of New York and other regulators. April 28 JPMorgan, one of two large clearing banks in the tri-party repurchase agreement market, said on Monday that it had met targets to reduce risks of short-term loans of concern to the Federal Reserve Bank of New York and other regulators.JPMorgan reduces repo credit extension that concerns regulators JPMorgan , one of two large clearing banks in the tri-party repurchase agreement market, said on Monday that it had met targets to reduce risks of short-term loans of concern to the Federal Reserve Bank of New York and other regulators.  
KMI,El Paso to buy natural gas assets from Kinder Morgan for $2 blnRPT-El Paso to buy natural gas assets from Kinder Morgan for $2 bln April 28 El Paso Pipeline Partners LP  said it would buy natural gas assets from Kinder Morgan Inc  for about $2 billion, including $1.01 billion of debt.  RPT-El Paso to buy natural gas assets from Kinder Morgan for $2 bln April 28 El Paso Pipeline Partners LP  said it would buy natural gas assets from Kinder Morgan Inc  for about $2 billion, including $1.01 billion of debt. April 28 El Paso Pipeline Partners LP  said it would buy natural gas assets from Kinder Morgan Inc  for about $2 billion, including $1.01 billion of debt.RPT-El Paso to buy natural gas assets from Kinder Morgan for $2 bln April 28 El Paso Pipeline Partners LP  said it would buy natural gas assets from Kinder Morgan Inc  for about $2 billion, including $1.01 billion of debt.  
L,Loews quarterly profit falls 75 percentUPDATE 1-Loews profit falls on losses tied to CNA's pension business sale * First-quarter net income $0.15/shr vs $0.62/shr last year  UPDATE 1-Loews profit falls on losses tied to CNA's pension business sale * First-quarter net income $0.15/shr vs $0.62/shr last year April 28 Hotel, energy and financial services conglomerate Loews Corp reported a 75 percent drop in quarterly profit as it booked a loss related to the pending sale of the annuity and pension deposit business of CNA Financial Corp.UPDATE 1-Loews profit falls on losses tied to CNA's pension business sale * First-quarter net income $0.15/shr vs $0.62/shr last year  
MA,Mastercard to stop services to sanctioned Russian banks MOSCOW, April 28 U.S. payment card firm MasterCard Inc will suspend services in the near future to cards issued by Russia's SMP bank and InvestCapitalbank, which were sanctioned on Monday by the United States, the payment company said. 
MRK,Reckitt Benckiser confirms talks to buy Merck unitRPT-Reckitt Benckiser confirms talks to buy Merck unitUPDATE 1-Reckitt Benckiser confirms talks to buy Merck unitReckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.  Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals. LONDON, April 28 Britain's Reckitt Benckiser Group Plc confirmed on Monday it was in talks to buy Merck & Co's consumer health business, the latest asset up for grabs in a wave of recent  pharmaceutical deals.Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.   UPDATE 1-Reckitt Benckiser confirms talks to buy Merck unitReckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.  Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals. LONDON, April 28 Britain's Reckitt Benckiser Group Plc confirmed on Monday it was in talks to buy Merck & Co's consumer health business, the latest asset up for grabs in a wave of recent  pharmaceutical deals.Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.  LONDON, April 28 Britain's Reckitt Benckiser Group confirmed on Monday it was in talks to buy Merck & Co Inc's consumer health business, the latest asset up for grabs in a wave of pharmaceutical deals.UPDATE 1-Reckitt Benckiser confirms talks to buy Merck unitReckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.  Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals. LONDON, April 28 Britain's Reckitt Benckiser Group Plc confirmed on Monday it was in talks to buy Merck & Co's consumer health business, the latest asset up for grabs in a wave of recent  pharmaceutical deals.Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.    RPT-Reckitt Benckiser confirms talks to buy Merck unitUPDATE 1-Reckitt Benckiser confirms talks to buy Merck unitReckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.  Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals. LONDON, April 28 Britain's Reckitt Benckiser Group Plc confirmed on Monday it was in talks to buy Merck & Co's consumer health business, the latest asset up for grabs in a wave of recent  pharmaceutical deals.Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.   UPDATE 1-Reckitt Benckiser confirms talks to buy Merck unitReckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.  Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals. LONDON, April 28 Britain's Reckitt Benckiser Group Plc confirmed on Monday it was in talks to buy Merck & Co's consumer health business, the latest asset up for grabs in a wave of recent  pharmaceutical deals.Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.  LONDON, April 28 Britain's Reckitt Benckiser Group confirmed on Monday it was in talks to buy Merck & Co Inc's consumer health business, the latest asset up for grabs in a wave of pharmaceutical deals.UPDATE 1-Reckitt Benckiser confirms talks to buy Merck unitReckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.  Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals. LONDON, April 28 Britain's Reckitt Benckiser Group Plc confirmed on Monday it was in talks to buy Merck & Co's consumer health business, the latest asset up for grabs in a wave of recent  pharmaceutical deals.Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.   LONDON, April 28 Britain's Reckitt Benckiser Group confirmed on Monday it was in talks to buy Merck & Co Inc's consumer health business, the latest asset up for grabs in a wave of pharmaceutical deals.RPT-Reckitt Benckiser confirms talks to buy Merck unitUPDATE 1-Reckitt Benckiser confirms talks to buy Merck unitReckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.  Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals. LONDON, April 28 Britain's Reckitt Benckiser Group Plc confirmed on Monday it was in talks to buy Merck & Co's consumer health business, the latest asset up for grabs in a wave of recent  pharmaceutical deals.Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.   UPDATE 1-Reckitt Benckiser confirms talks to buy Merck unitReckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.  Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals. LONDON, April 28 Britain's Reckitt Benckiser Group Plc confirmed on Monday it was in talks to buy Merck & Co's consumer health business, the latest asset up for grabs in a wave of recent  pharmaceutical deals.Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.  LONDON, April 28 Britain's Reckitt Benckiser Group confirmed on Monday it was in talks to buy Merck & Co Inc's consumer health business, the latest asset up for grabs in a wave of pharmaceutical deals.UPDATE 1-Reckitt Benckiser confirms talks to buy Merck unitReckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.  Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals. LONDON, April 28 Britain's Reckitt Benckiser Group Plc confirmed on Monday it was in talks to buy Merck & Co's consumer health business, the latest asset up for grabs in a wave of recent  pharmaceutical deals.Reckitt Benckiser confirms talks to buy Merck unit LONDON Britain's Reckitt Benckiser Group Plc  confirmed on Monday it was in talks to buy Merck & Co's  consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.    
MSFT,Bill Gates, in Communist newspaper, urges more in China to help poorMicrosoft rushes to fix browser after attacks; no fix for XP usersBill Gates, in Communist newspaper, urges more in China to help poorAOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.     AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    SHANGHAI Microsoft founder Bill Gates on Monday took to the pages of the People's Daily, the mouthpiece newspaper of China's ruling Communist Party, to encourage people in China to do more for the poor.AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.      Bill Gates, in Communist newspaper, urges more in China to help poorAOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.     AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    SHANGHAI Microsoft founder Bill Gates on Monday took to the pages of the People's Daily, the mouthpiece newspaper of China's ruling Communist Party, to encourage people in China to do more for the poor.AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.     BOSTON Microsoft Corp is rushing to fix a bug in its widely used Internet Explorer web browser after a computer security firm disclosed the flaw over the weekend, saying hackers have already exploited it in attacks on some U.S. companies.Bill Gates, in Communist newspaper, urges more in China to help poorAOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.     AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    SHANGHAI Microsoft founder Bill Gates on Monday took to the pages of the People's Daily, the mouthpiece newspaper of China's ruling Communist Party, to encourage people in China to do more for the poor.AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.       Microsoft rushes to fix browser after attacks; no fix for XP usersBill Gates, in Communist newspaper, urges more in China to help poorAOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.     AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    SHANGHAI Microsoft founder Bill Gates on Monday took to the pages of the People's Daily, the mouthpiece newspaper of China's ruling Communist Party, to encourage people in China to do more for the poor.AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.      Bill Gates, in Communist newspaper, urges more in China to help poorAOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.     AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    SHANGHAI Microsoft founder Bill Gates on Monday took to the pages of the People's Daily, the mouthpiece newspaper of China's ruling Communist Party, to encourage people in China to do more for the poor.AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.     BOSTON Microsoft Corp is rushing to fix a bug in its widely used Internet Explorer web browser after a computer security firm disclosed the flaw over the weekend, saying hackers have already exploited it in attacks on some U.S. companies.Bill Gates, in Communist newspaper, urges more in China to help poorAOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.     AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    SHANGHAI Microsoft founder Bill Gates on Monday took to the pages of the People's Daily, the mouthpiece newspaper of China's ruling Communist Party, to encourage people in China to do more for the poor.AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.      SHANGHAI, April 28 Microsoft founder Bill Gates on Monday took to the pages of the People's Daily, the mouthpiece newspaper of China's ruling Communist Party, to encourage people in China to do more for the poor.Microsoft rushes to fix browser after attacks; no fix for XP usersBill Gates, in Communist newspaper, urges more in China to help poorAOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.     AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    SHANGHAI Microsoft founder Bill Gates on Monday took to the pages of the People's Daily, the mouthpiece newspaper of China's ruling Communist Party, to encourage people in China to do more for the poor.AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.      Bill Gates, in Communist newspaper, urges more in China to help poorAOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.     AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    SHANGHAI Microsoft founder Bill Gates on Monday took to the pages of the People's Daily, the mouthpiece newspaper of China's ruling Communist Party, to encourage people in China to do more for the poor.AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.     BOSTON Microsoft Corp is rushing to fix a bug in its widely used Internet Explorer web browser after a computer security firm disclosed the flaw over the weekend, saying hackers have already exploited it in attacks on some U.S. companies.Bill Gates, in Communist newspaper, urges more in China to help poorAOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.     AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    SHANGHAI Microsoft founder Bill Gates on Monday took to the pages of the People's Daily, the mouthpiece newspaper of China's ruling Communist Party, to encourage people in China to do more for the poor.AOL, Microsoft lure advertisers with TV-style showsU.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.    U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   NEW YORK/LOS ANGELES Technology powerhouses like Microsoft Corp and AOL Inc are flexing their muscles as storytellers, parading TV network-style shows before advertisers at an annual digital content showcase in New York next week.U.S. top court declines to hear Microsoft antitrust caseU.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.   U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  WASHINGTON, April 28 The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.U.S. Supreme Court declines to hear Microsoft antitrust caseUPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.  UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks. WASHINGTON The U.S. Supreme Court on Monday brought an end to Novell Inc's antitrust claims against Microsoft Corp that date back 20 years to the development of Windows 95 software.UPDATE 2-US, UK advise avoiding Internet Explorer until bug fixed BOSTON, April 28 The U.S. and UK governments on Monday advised computer users to consider using alternatives to Microsoft Corp's Internet Explorer browser until the company fixes a security flaw that hackers used to launch attacks.       
MYL,Meda rejects Mylan proposalNORDIC STOCKS - Factors to watch on April 28Meda board rejects new Mylan offerBRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy  BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy STOCKHOLM Swedish drugmaker Meda  has rejected an improved takeover offer from U.S. generics firm Mylan , saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy   Meda board rejects new Mylan offerBRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy  BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy STOCKHOLM Swedish drugmaker Meda  has rejected an improved takeover offer from U.S. generics firm Mylan , saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy  HELSINKI, April 28 The following stocks may be affected by newspaper reports and other factors on Monday:Meda board rejects new Mylan offerBRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy  BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy STOCKHOLM Swedish drugmaker Meda  has rejected an improved takeover offer from U.S. generics firm Mylan , saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy    NORDIC STOCKS - Factors to watch on April 28Meda board rejects new Mylan offerBRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy  BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy STOCKHOLM Swedish drugmaker Meda  has rejected an improved takeover offer from U.S. generics firm Mylan , saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy   Meda board rejects new Mylan offerBRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy  BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy STOCKHOLM Swedish drugmaker Meda  has rejected an improved takeover offer from U.S. generics firm Mylan , saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy  HELSINKI, April 28 The following stocks may be affected by newspaper reports and other factors on Monday:Meda board rejects new Mylan offerBRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy  BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy STOCKHOLM Swedish drugmaker Meda  has rejected an improved takeover offer from U.S. generics firm Mylan , saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy   STOCKHOLM, April 28 Swedish drug maker Meda  said on Monday it had rejected a new offer from U.S. generics firm Mylan to acquire it.NORDIC STOCKS - Factors to watch on April 28Meda board rejects new Mylan offerBRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy  BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy STOCKHOLM Swedish drugmaker Meda  has rejected an improved takeover offer from U.S. generics firm Mylan , saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy   Meda board rejects new Mylan offerBRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy  BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy STOCKHOLM Swedish drugmaker Meda  has rejected an improved takeover offer from U.S. generics firm Mylan , saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy  HELSINKI, April 28 The following stocks may be affected by newspaper reports and other factors on Monday:Meda board rejects new Mylan offerBRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy  BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy STOCKHOLM Swedish drugmaker Meda  has rejected an improved takeover offer from U.S. generics firm Mylan , saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy    
NOV,National Oilwell profit beats on strong demand for drilling services April 28 National Oilwell Varco Inc's  first-quarter profit beat analyst estimates, helped by strong demand for its services that prepare oil and gas wells for production. 
NEM,Newmont terminates merger talks with BarrickCANADA STOCKS-Bank, energy shares push TSX higher; Barrick dropsUPDATE 4-Barrick, Newmont trade barbs after merger talks implodeCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di  CANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di * Sources says reporting structure in new entity was an issueCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di   UPDATE 4-Barrick, Newmont trade barbs after merger talks implodeCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di  CANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di * Sources says reporting structure in new entity was an issueCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di  * TSX rises 21.81 points, or 0.15 percent, to 14,555.38     * Eight of the 10 main index sectors advance     * Barrick drops 2 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index edged higher on Monday as gains in financial and energy shares provided support, offsetting a drop in shares of Barrick Gold Corp after the miner said merger talks with Newmont Mining had been terminated.     Newmont said it had ended the discussions witUPDATE 4-Barrick, Newmont trade barbs after merger talks implodeCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di  CANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di * Sources says reporting structure in new entity was an issueCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di    CANADA STOCKS-Bank, energy shares push TSX higher; Barrick dropsUPDATE 4-Barrick, Newmont trade barbs after merger talks implodeCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di  CANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di * Sources says reporting structure in new entity was an issueCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di   UPDATE 4-Barrick, Newmont trade barbs after merger talks implodeCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di  CANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di * Sources says reporting structure in new entity was an issueCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di  * TSX rises 21.81 points, or 0.15 percent, to 14,555.38     * Eight of the 10 main index sectors advance     * Barrick drops 2 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index edged higher on Monday as gains in financial and energy shares provided support, offsetting a drop in shares of Barrick Gold Corp after the miner said merger talks with Newmont Mining had been terminated.     Newmont said it had ended the discussions witUPDATE 4-Barrick, Newmont trade barbs after merger talks implodeCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di  CANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di * Sources says reporting structure in new entity was an issueCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di   TORONTO, April 28 Newmont Mining Corp  has terminated merger talks with Barrick Gold Corp  , Barrick said on Monday.CANADA STOCKS-Bank, energy shares push TSX higher; Barrick dropsUPDATE 4-Barrick, Newmont trade barbs after merger talks implodeCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di  CANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di * Sources says reporting structure in new entity was an issueCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di   UPDATE 4-Barrick, Newmont trade barbs after merger talks implodeCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di  CANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di * Sources says reporting structure in new entity was an issueCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di  * TSX rises 21.81 points, or 0.15 percent, to 14,555.38     * Eight of the 10 main index sectors advance     * Barrick drops 2 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index edged higher on Monday as gains in financial and energy shares provided support, offsetting a drop in shares of Barrick Gold Corp after the miner said merger talks with Newmont Mining had been terminated.     Newmont said it had ended the discussions witUPDATE 4-Barrick, Newmont trade barbs after merger talks implodeCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di  CANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di * Sources says reporting structure in new entity was an issueCANADA STOCKS-TSX steady as bank, energy shares gain; Barrick falls * TSX down 2.66 points, or 0.02 percent, at 14,530.91     * Seven of 10 main index sectors advance     * Barrick drops 3 percent after Newmont ends merger talks      By John Tilak     TORONTO, April 28 Canada's main stock index was little changed on Monday as weakness in shares of Barrick Gold Corp and concerns about the volatile situation in Ukraine were offset by gains in the financial and energy sectors.     Barrick shed 3.1 percent after Newmont Mining said it had ended merger di    
PFE,CORRECTED-US STOCKS-Nasdaq falls, led by Facebook and Amazon; Dow upAstraZeneca rejects Pfizer talks, says confident in strategyUS STOCKS SNAPSHOT-S&P; 500 ends up with Apple after volatile sessionDeals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.      Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     NEW YORK, April 28 The S&P; 500 ended higher on Monday after a volatile session, as gains in Apple and Pfizer helped offset another round of selling in some high-growth tech shares.Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.       US STOCKS SNAPSHOT-S&P; 500 ends up with Apple after volatile sessionDeals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.      Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     NEW YORK, April 28 The S&P; 500 ended higher on Monday after a volatile session, as gains in Apple and Pfizer helped offset another round of selling in some high-growth tech shares.Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.      LONDON Britain's AstraZeneca urged its shareholders to take no action over the approach by U.S. drugmaker Pfizer Inc on Monday and said it remained confident in its independent strategy.US STOCKS SNAPSHOT-S&P; 500 ends up with Apple after volatile sessionDeals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.      Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     NEW YORK, April 28 The S&P; 500 ended higher on Monday after a volatile session, as gains in Apple and Pfizer helped offset another round of selling in some high-growth tech shares.Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.        AstraZeneca rejects Pfizer talks, says confident in strategyUS STOCKS SNAPSHOT-S&P; 500 ends up with Apple after volatile sessionDeals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.      Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     NEW YORK, April 28 The S&P; 500 ended higher on Monday after a volatile session, as gains in Apple and Pfizer helped offset another round of selling in some high-growth tech shares.Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.       US STOCKS SNAPSHOT-S&P; 500 ends up with Apple after volatile sessionDeals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.      Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     NEW YORK, April 28 The S&P; 500 ended higher on Monday after a volatile session, as gains in Apple and Pfizer helped offset another round of selling in some high-growth tech shares.Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.      LONDON Britain's AstraZeneca urged its shareholders to take no action over the approach by U.S. drugmaker Pfizer Inc on Monday and said it remained confident in its independent strategy.US STOCKS SNAPSHOT-S&P; 500 ends up with Apple after volatile sessionDeals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.      Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     NEW YORK, April 28 The S&P; 500 ended higher on Monday after a volatile session, as gains in Apple and Pfizer helped offset another round of selling in some high-growth tech shares.Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.       (Corrects first paragraph to show Bank of America weighed on S&P; 500, not Dow)AstraZeneca rejects Pfizer talks, says confident in strategyUS STOCKS SNAPSHOT-S&P; 500 ends up with Apple after volatile sessionDeals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.      Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     NEW YORK, April 28 The S&P; 500 ended higher on Monday after a volatile session, as gains in Apple and Pfizer helped offset another round of selling in some high-growth tech shares.Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.       US STOCKS SNAPSHOT-S&P; 500 ends up with Apple after volatile sessionDeals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.      Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     NEW YORK, April 28 The S&P; 500 ended higher on Monday after a volatile session, as gains in Apple and Pfizer helped offset another round of selling in some high-growth tech shares.Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.      LONDON Britain's AstraZeneca urged its shareholders to take no action over the approach by U.S. drugmaker Pfizer Inc on Monday and said it remained confident in its independent strategy.US STOCKS SNAPSHOT-S&P; 500 ends up with Apple after volatile sessionDeals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.      Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     NEW YORK, April 28 The S&P; 500 ended higher on Monday after a volatile session, as gains in Apple and Pfizer helped offset another round of selling in some high-growth tech shares.Deals of the day- Mergers and acquisitionsUS STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.     US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)US STOCKS-S&P; 500 ends up with Apple, Pfizer; Nasdaq dipsPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.    Pfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   * Pfizer works on next move in takeover bid for AstrazenecaPfizer chases AstraZeneca for potential $100 billion dealUS STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.   US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  LONDON/NEW YORK U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite a potential $100 billion takeover and was rebuffed, raising investor expectations it will have to increase its offer to close the deal.US STOCKS-S&P; 500, Dow end up after late rebound; Apple, Pfizer liftUPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.  UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. (Updates close with jump in Agenus; adds Gogo's shares down after the bell)UPDATE 1-Actavis sues U.S. drug regulator over generic Celebrex April 28 Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.        
QCOM,STMicro posts lower first-quarter revenue, smaller loss SAN FRANCISCO, April 28 STMicroelectronics  posted lower first-quarter revenue and a loss that narrowed after the European chipmaker exited its mobile joint venture with ST-Ericsson. 
STJ,STMicro posts lower first-quarter revenue, smaller loss SAN FRANCISCO, April 28 STMicroelectronics  posted lower first-quarter revenue and a loss that narrowed after the European chipmaker exited its mobile joint venture with ST-Ericsson. 
WMT,Wal-Mart paid $334 mln to end India partnership MUMBAI, April 28 Wal-Mart Stores Inc  paid about $234 million in debt related to the purchase of a stake in its Indian joint venture with Bharti Enterprises, which the U.S. retailer ended in October last year, according to its 2014 annual report. 
